TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Radioiodine (RI) ablation following thyroid-stimulating hormone suppression is an effective treatment for papillary thyroid cancer (PTC), typically leading to favorable outcomes. However, RI-refractory tumors exhibit aggressive behavior and poor prognoses. Recent studies highlight the role of genetic abnormalities in PTC signaling pathways, including the activation of telomerase reverse transcriptase (TERT), and the correlation of mutations with adverse outcomes. Methods: This study analyzed mutations in BRAF V600E and the TERT-promoter genes, comparing clinicopathological features between RI-refractory and RI-responsive PTCs. Among 82 RI-refractory patients, formalin-fixed, paraffin-embedded tissues from initial surgeries were available for 26. Another 89 without distant metastasis over 5 years formed a matched RI-responsive control group. Results: Histopathologically, RI-refractory PTCs showed increased frequencies of small tumor clusters without fibrovascular cores, hobnail features, and a high height-to-width ratio of tumor cells. These tumors were more likely to exhibit necrosis, mitosis, lymph node metastasis, extrathyroidal extension, and involvement of resection margins. TERT-promoter mutations were statistically significantly associated with these aggressive clinicopathologic features. Immunohistochemically, decreased expression of sodium iodide symporter and thyroglobulin stimulating hormone receptor proteins was common in RI-refractory PTCs, along with lower levels of oncogenic proteins such as vascular endothelial cell growth factor, vascular endothelial cell growth factor receptor 2, and nuclear factor kappa-light-chain-enhancer of activated B cells. Total loss of PTEN expression was occasionally observed. In contrast, all cases tested positive for cytoplasmic β-catenin. Conclusions: RI-refractory PTCs are linked to TERT mutations and exhibit specific aggressive histopathologic features, particularly in tumor centers.
Abstract
Background: Radioiodine (RI) ablation following thyroid-stimulating hormone suppression is an effective treatment for papillary thyroid cancer (PTC), typically leading to favorable outcomes. However, RI-refractory tumors exhibit aggressive behavior and poor prognoses. Recent studies highlight the role of genetic abnormalities in PTC signaling pathways, including the activation of telomerase reverse transcriptase (TERT), and the correlation of mutations with adverse outcomes. Methods: This study analyzed mutations in BRAF V600E and the TERT-promoter genes, comparing clinicopathological features between RI-refractory and RI-responsive PTCs. Among 82 RI-refractory patients, formalin-fixed, paraffin-embedded tissues from initial surgeries were available for 26. Another 89 without distant metastasis over 5 years formed a matched RI-responsive control group. Results: Histopathologically, RI-refractory PTCs showed increased frequencies of small tumor clusters without fibrovascular cores, hobnail features, and a high height-to-width ratio of tumor cells. These tumors were more likely to exhibit necrosis, mitosis, lymph node metastasis, extrathyroidal extension, and involvement of resection margins. TERT-promoter mutations were statistically significantly associated with these aggressive clinicopathologic features. Immunohistochemically, decreased expression of sodium iodide symporter and thyroglobulin stimulating hormone receptor proteins was common in RI-refractory PTCs, along with lower levels of oncogenic proteins such as vascular endothelial cell growth factor, vascular endothelial cell growth factor receptor 2, and nuclear factor kappa-light-chain-enhancer of activated B cells. Total loss of PTEN expression was occasionally observed. In contrast, all cases tested positive for cytoplasmic β-catenin. Conclusions: RI-refractory PTCs are linked to TERT mutations and exhibit specific aggressive histopathologic features, particularly in tumor centers.
참고문헌 (31)
- Kang MJ, "Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2020", Cancer Res Treat, 55, pp.385~399 (2023)
- Kitahara CM, "The changing incidence of thyroid cancer", Nat Rev Endocrinol, 12, pp.646~653 (2016)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : what is new and what has changed?", Cancer, 123, pp.372~381 (2017)
- Mian C, "Molecular characteristics in papillary thyroid cancers(PTCs)with no 131I uptake", Clin Endocrinol (Oxf), 68, pp.108~116 (2008)
- Durante C, "Long-term outcome of 444patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91, pp.2892~2899 (2006)
- Xing M, "Molecular pathogenesis and mechanisms of thyroid cancer", Nat Rev Cancer, 13, pp.184~199 (2013)
- Liu X, "TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer", J Clin Endocrinol Metab, 99, pp.E1130~E1136 (2014)
- Xing M, "BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence", J Clin Oncol, 32, pp.2718~2726 (2014)
- Wong KP, "New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma : literature review", J Thyroid Res, 2012, pp.818204~ (2012)
- Lloyd RV, "WHO classification of tumours of endocrine organs", pp.65~143 (2017), International Agency for Research on Cancer
- Amin MB, "American Cancer Society. AJCC cancer staging manual", pp.873~890 (2017), Springer
- Amacher AM, "Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma : a possible manifestation of highgrade transformation", Am J Surg Pathol, 39, pp.260~265 (2015)
- Asioli S, "Papillary thyroid carcinoma with hobnail features : histopathologic criteria to predict aggressive behavior", Hum Pathol, 44, pp.320~328 (2013)
- Kim YH, "A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma", Hum Pathol, 45, pp.1483~1488 (2014)
- Kimura ET, "High prevalence of BRAF mutations in thyroid cancer : genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- Liu R, "Mutations of the TERT promoter are associated with aggressiveness and recurrence", distant metastasis of papillary thyroid carcinoma, 2020, pp.20, 50~
- Baloch ZW, "Overview of the 2022 WHO classification of thyroid neoplasms", Endocr Pathol, 33, pp.27~63 (2022)
- Asioli S, "Papillary thyroid carcinoma with prominent hobnail features : a new aggressive variant of moderately differentiated papillary carcinoma : a clinicopathologic, immunohistochemical, and molecular study of eight cases", Am J Surg Pathol, 34, pp.44~52 (2010)
- Ricarte-Filho JC, "Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK-3CA, and AKT1", Cancer Res, 69, pp.4885~4893 (2009)
- Hartwig FP, "Telomeres and tissue engineering : the potential roles of TERT in VEGF-mediated angiogenesis", Stem Cell Rev Rep, 8, pp.1275~1281 (2012)
- Sodre AK, "Association of low sodiumiodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining", J Clin Endocrinol Metab, 93, pp.4141~4145 (2008)
- Wei S, "Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma", Int J Clin Oncol, 19, pp.800~804 (2014)
- Vinagre J, "Telomerase promoter mutations in cancer : an emerging molecular biomarker?", Virchows Arch, 465, pp.119~133 (2014)
- Xing M, "BRAF mutation in papillary thyroid cancer : pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
- So YK, "Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma", Ann Surg Oncol, 19, pp.990~995 (2012)
- Durante C, "BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism", J Clin Endocrinol Metab, 92, pp.2840~2843 (2007)
- Liu D, "Suppression of BRAF", MEK, Clin Cancer Res, pp.2007, 13[DOI]
- Kogai T, "Phosphoinositide-3-kinase inhibition induces sodium", iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells, 2008, pp.199, 243~252
- Miyake N, "Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas", Pathol Int, 51, pp.680~685 (2001)
- Oh WJ, "Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features", Korean J Pathol, 48, pp.201~208 (2014)
- Li X, "The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers", Thyroid, 23, pp.209~218 (2013)